• GDC-0941: PI3K Inhibitor Protocols for Cancer Research Succe

  2026-05-19

  GDC-0941 empowers translational researchers with precise PI3K/Akt pathway inhibition, enabling robust analysis of proliferation and resistance in diverse cancer models. This guide delivers step-by-step workflows, troubleshooting strategies, and cutting-edge insights to maximize experimental reproducibility and impact.

• Tropisetron Hydrochloride: Applied 5-HT3 Receptor Antagonist

  2026-05-18

  Tropisetron Hydrochloride delivers precise, dual-action modulation of serotonin and nicotinic pathways, setting a new standard for reproducible neuroscience and renal transporter research. This guide decodes advanced experimental setups, troubleshooting strategies, and protocol optimizations for leveraging APExBIO’s high-purity 5-HT3 receptor antagonist in sophisticated in vitro and cell-based assays.

• Linarin from Lycii Cortex Reverses Insulin Resistance via c-

  2026-05-18

  This study identifies Linarin as the principal bioactive compound in Lycii Cortex that ameliorates insulin resistance and inflammation through the c-FOS/ARG2 signaling axis. Using network pharmacology, molecular docking, and in vitro and in vivo glucose uptake assays, the authors provide mechanistic insights relevant for diabetes research and metabolic disease modeling.

• hiPSC-Derived Intestinal Organoids Enable Human-Relevant PK

  2026-05-17

  This study presents a 3D culture protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, offering improved physiological relevance and self-renewal for pharmacokinetic research. The organoid-derived intestinal epithelial cells exhibit mature drug-metabolizing enzyme activities, providing a superior model for in vitro studies of cytochrome P450 metabolism and drug absorption.

• gamma-Glu-Cys (γ-Glu-Cys): A Systems Approach to Glutathione

  2026-05-16

  Explore gamma-Glu-Cys (γ-Glu-Cys) as a pivotal intermediate in glutathione metabolism research, with a systems-level perspective on microbial enzyme selection and substrate optimization. This article delivers actionable insights for advanced peptide biosynthesis and plant stress adaptation studies.

• KU-55933 ATM Kinase Inhibitor: Precision in DNA Damage Respo

  2026-05-15

  KU-55933 offers researchers a potent and selective tool for dissecting ATM-dependent DNA damage pathways, enabling precise cell cycle and metabolic studies. This article details advanced workflows, troubleshooting strategies, and new insights from nuclear cGAS research, setting the foundation for robust and reproducible results in cancer and genome stability research.

• ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR

  2026-05-15

  This study introduces a combinatorial library of ROS-degradable lipid nanoparticles, identifying BAmP-TK-12 as a delivery vehicle that enables preferential mRNA release and gene expression in tumor cells. The approach demonstrates targeted depletion of mutant RAS in cancer models, opening avenues for selective mRNA-based therapeutics.

• Neomycin Sulfate: Mechanistic Power & Strategy in Translatio

  2026-05-14

  This thought-leadership article explores how Neomycin sulfate, an aminoglycoside antibiotic, drives innovative translational research by bridging nucleic acid structure-function studies, ion channel analysis, and emerging immune-microbiome insights. Blending mechanistic explanation, literature-backed protocol guidance, and actionable outlooks, it offers strategic pathways for researchers seeking to harness Neomycin sulfate for advanced biomedical discovery.

• Rucaparib (AG-014699): Precision Tools for DNA Damage Respon

  2026-05-14

  Rucaparib (AG-014699) delivers unique advantages for dissecting the DNA damage response, offering precise PARP1 inhibition and radiosensitization—especially in cancer biology research. This article delivers actionable workflows, troubleshooting strategies, and insight into leveraging recent advances in regulated cell death signaling to maximize the utility of Rucaparib from APExBIO.

• High-Throughput BBB Permeability Prediction Using LLC-PK1-MD

  2026-05-13

  This study establishes a high-throughput in vitro model integrating LLC-PK1-MOCK/MDR1 cells and lysosomal trapping correction to predict blood-brain barrier (BBB) permeability. The model demonstrates robust predictive power for CNS drug screening, streamlining early-stage evaluation of brain-penetrant compounds.

• PDGF Receptor Inhibition: Mechanistic Insights & Translation

  2026-05-13

  This thought-leadership article explores the strategic and mechanistic landscape of JNJ-10198409, a potent platelet-derived growth factor receptor inhibitor, for translational researchers in oncology and fibrosis. Integrating foundational insights from plant-virus co-survival strategies, the article presents protocol guidance, competitive landscape evaluation, and a future-facing outlook on PDGF pathway blockade. APExBIO's JNJ-10198409 is positioned as an enabling tool for next-generation studies of tumor growth, angiogenesis, and fibrotic disease.

• ABT-199 (GDC-0199), Bcl-2 Inhibitor: Practical Lab Guidance

  2026-05-12

  ABT-199 (GDC-0199), also known as Venetoclax, provides potent and highly selective inhibition of BCL-2, making it a focused tool for dissecting apoptosis mechanisms in hematologic malignancy research. It is best suited for experimental setups requiring minimal off-target effects, particularly where platelet sparing and selective mitochondrial pathway interrogation are priorities. It should not be used for diagnostic or clinical purposes, nor in systems dependent on Mcl-1 or unrelated anti-apoptotic proteins.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit: Precision Pr

  2026-05-12

  The HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit empowers researchers to generate high-sensitivity, customizable fluorescent RNA probes for in situ and Northern blot hybridization workflows. Its tunable Cy5-UTP incorporation and robust yields provide a flexible platform for optimizing probe performance in advanced gene expression and cell signaling studies.

• ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR

  2026-05-11

  This study reports the first combinatorial library of ROS-degradable lipid nanoparticles for mRNA delivery, achieving tumor cell selectivity by leveraging elevated intracellular ROS levels. The approach demonstrates superior antitumor efficacy by enabling targeted depletion of mutant RAS in cancer cells, with implications for precision mRNA therapeutics.

• LY2886721: Precision BACE Inhibitor for Alzheimer’s Research

  2026-05-11

  LY2886721 is a potent, oral BACE1 inhibitor enabling targeted amyloid beta reduction in translational Alzheimer's disease models. This article details best-practice workflows, troubleshooting insights, and real-world protocol optimizations that maximize the compound's reliability and data quality in neurodegeneration research.

405 records 8/27 page Previous Next First page 上5页 678910 下5页 Last page